Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880357 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 485
- Enrollment target
NCT03880357 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 485 participants.
The verdict
NCT03880357, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 485 participants
- Enrollment target
Study Summary
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.
Interventions
- DRUG Taclonex®
- DRUG Betamethasone Scalp Suspension 0.064%;0.0005%
- DRUG Placebo topical suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03880357
The ClinicalTrials.gov registry entry for NCT03880357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Taclonex® is the first listed.
NCT03880357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03880357 about?
NCT03880357 is a clinical study titled "To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis". To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of scalp psoriasis.
What is the current status of trial NCT03880357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 485 participants. The study started on 2018-10-22. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03880357?
The interventions under investigation include: Taclonex® (DRUG), Betamethasone Scalp Suspension 0.064%;0.0005% (DRUG), Placebo topical suspension (DRUG).
Who is sponsoring clinical trial NCT03880357?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.